Press Releases AstraZeneca PLC Nasdaq Stockholm

Equities

AZN

GB0009895292

Market Closed - Nasdaq Stockholm Other stock markets 11:29:38 2024-05-31 EDT			5-day change	1st Jan Change
1,643 ^SEK	+1.08%		-1.76%	+21.39%

09:03pm	Astra's Enhertu breast cancer trial shows 'unprecedented' results	RE
04:58pm	Astra's Enhertu delays breast cancer in patients with low HER2 levels	RE

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

AstraZeneca : Tagrisso reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial	02:08pm	PU
Daiichi Sankyo - Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	05-28	AQ
Expansion of AstraZeneca's flagship health equity programme Healthy Heart Africa	05-28	AQ
Expansion of AstraZeneca’s flagship health equity programme Healthy Heart Africa The programme aims to improve health outcomes, with a focus on increasing awareness of the symptoms and risks of hypertension	05-28	AQ
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	05-27	BU
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)	05-23	BU
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024	05-22	BU
Astrazeneca looks to double revenue in 'new era of growth'	05-22	AQ
INSIDE XP POWER REJECTS BID ...	05-22	AQ
AstraZeneca : Oncology presentation	05-21	PU
AstraZeneca : Rare Disease presentation	05-21	PU
AstraZeneca : BioPharmaceuticals presentation	05-21	PU
AstraZeneca : Investor Day Agenda	05-21	PU
AstraZeneca : Investor Day Biographies	05-21	PU
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030	05-21	BU
Astrazeneca set to build cancer drug plant in Singapore	05-21	AQ
AstraZeneca announces $1.5b ADC manufacturing facility	05-20	AQ
Astrazeneca - New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease	05-20	AQ
AstraZeneca : plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore - Form 6-K	05-20	PU
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease	05-19	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm